-
1Academic Journal
Συγγραφείς: S. A. Ivanov, L. O. Petrov, V. V. Kucherov, A. G. Isaeva, A. P. Petrosian, A. A. Izmailov, С. А. Иванов, Л. О. Петров, В. В. Кучеров, А. Г. Исаева, А. П. Петросян, А. А. Измаилов
Πηγή: Research and Practical Medicine Journal; Том 10, № 1 (2023); 134-142 ; Research'n Practical Medicine Journal; Том 10, № 1 (2023); 134-142 ; 2410-1893 ; 10.17709/2410-1893-2023-10-1
Θεματικοί όροι: трансартериальная химиоэмболизация, hepatocellular carcinoma, liver chemoembolization, treatment complications, transarterial chemoembolization, гепатоцеллюлярная карцинома, химиоэмболизация печени, осложнения лечения
Περιγραφή αρχείου: application/pdf
Relation: https://www.rpmj.ru/rpmj/article/view/815/545; Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). Под ред. А. Д. Каприна, В. В. Старинского, А. О. Шахзадовой. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020, 252 с. Доступно по: https://glavonco.ru/cancer_register/Забол_2019_Электр.pdf, Дата обращения: 29.10.2022.; Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424. https://doi.org/10.3322/caac.21492. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313; Raoul JL, Gilabert M, Piana G. How to define transarterial chemoembolization failure or refractoriness: a European perspective. Liver Cancer. 2014 May;3(2):119–124. https://doi.org/10.1159/000343867; Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018 Mar 31;391(10127):1301–1314. https://doi.org/10.1016/s0140‑6736(18)30010‑2; Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma.Gastroenterology.2014 Jun;146(7):1691–700.e3.https://doi.org/10.1053/j.gastro.2014.02.032; Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate‑stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014 Sep;11(9):525–535. https://doi.org/10.1038/nrclinonc.2014.122; Yamada R, Nakamura K. [Transcatheter arterial embolization therapy (author’s transl)]. Nihon Rinsho. 1982;40(1):183–190. Japanese.; Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology. 2016 Jul;64(1):106–116. https://doi.org/10.1002/hep.28453; Angle JF, Siddiqi NH, Wallace MJ, Kundu S, Stokes L, Wojak JC, Cardella JF; Society of Interventional Radiology Standards of Practice Committee. Quality improvement guidelines for percutaneous transcatheter embolization: Society of Interventional Radiology Standards of Practice Committee. J Vasc Interv Radiol. 2010 Oct;21(10):1479–1486. https://doi.org/10.1016/j.jvir.2010.06.014; Grover I, Ahmad N, Googe AB. Hepatogastric Fistula following Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma. Case Rep Gastroenterol. 2014 Oct 3;8(3):286–290. https://doi.org/10.1159/000368302; Chen LT, Chen CY, Jan CM, Wang WM, Lan TS, Hsieh MY, Liu GC. Gastrointestinal tract involvement in hepatocellular carcinoma: clinical, radiological and endoscopic studies. Endoscopy. 1990 May;22(3):118–123. https://doi.org/10.1055/s‑2007‑1012815; Hashimoto M, Watanabe G, Matsuda M, Yamamoto T, Tsutsumi K, Tsurumaru M: Case report: gastrointestinal bleeding from a hepatocellular carcinoma invading the transverse colon. J Gastroenterol Hepatol. 1996;11(8):765–767. https://doi.org/10.1111/j.1440‑1746.1996.tb00328.x; Park MS, Kim KW, Yu JS, Kim MJ, Yoon SW, Chung KW, et al. Radiologic findings of gastrointestinal tract involvement in hepatocellular carcinoma. J Comput Assist Tomogr. 2002 Jan‑Feb;26(1):95–101. https://doi.org/10.1097/00004728‑200201000‑00014; Sayana H, Yousef O, Clarkston WK. Massive upper gastrointestinal hemorrhage due to invasive hepatocellular carcinoma and hepato‑gastric fistula. World J Gastroenterol. 2013 Nov 14;19(42):7472–7475. https://doi.org/10.3748/wjg.v19.i42.7472; https://www.rpmj.ru/rpmj/article/view/815
-
2Academic Journal
Συγγραφείς: Z. Ya. Vagidova, A. V. Vodovatov, I. K. Romanovich, A. A. Stanzhevsky, A. A. Polikarpov, З. Я. Вагидова, А. А. Водоватов, И. К. Романович, А. А. Станжевский, А. А. Поликарпов
Πηγή: Radiatsionnaya Gygiena = Radiation Hygiene; Том 14, № 2 (2021); 83-88 ; Радиационная гигиена; Том 14, № 2 (2021); 83-88 ; 2409-9082 ; 1998-426X ; 10.21514/1998-426X-2021-14-2
Θεματικοί όροι: произведение дозы на площадь, optimization, effective dose, hepatic arterial chemoembolization, dose–area product, оптимизация, эффективная доза, химиоэмболизация печени
Περιγραφή αρχείου: application/pdf
Relation: https://www.radhyg.ru/jour/article/view/803/742; Chemoembolization T. Quality improvement guidelines for transarterial chemoembolization and embolization of hepatic malignancy // Journal of Vascular and Interventional Radiology: JVIR. 2017. Vol. 28. P. 1210-1223.; Полехин А.С., Таразов П.Г., Поликарпов А.А. Гранов Д.А. Химиоэмболизация печеночной артерии в лечении больных гепатоцеллюлярным раком на фоне выраженного цирроза печени // Вестник хирургии имени И.И. Грекова. 2019. Т. 178, №. 6. С. 29-35.; Гранов Д.А., Полехин А.С., Таразов П.Г., и др. Химиоэмболизация печеночных артерий у больных гепатоцеллюлярным раком на фоне цирроза перед трансплантацией печени: прогностическое значение концентрации альфафетопротеина // Вестник трансплантологии и искусственных органов. 2021. Т. 22, №. 4. С. 52-57. DOI:10.15825/1995-1191-2020-4-52-57; Dauer L.T., Thornton R., Boylan D.C., et al. Organ and effective dose estimates for patients undergoing hepatic arterial embolization for treatment of liver malignancy //Medical Physics. 2011. Vol. 38, №. 2. P. 736-742. DOI:10.1118/1.3533685.; Brambilla M., Cannillo B., Guzzardi G., et al. Conversion factors for effective dose and organ doses with the air kerma area product in patients undergoing percutaneous transhepatic biliary drainage and trans arterial chemoembolization // Physica Medica. 2020. Vol. 72. P. 7-15. DOI:10.1016/j.ejmp.2020.03.003.; Karavasilis E., Dimitriadis A., Gonis H., et al. Dose coefficients for liver chemoembolisation procedures using Monte Carlo code // Radiation Protection Dosimetry. 2016. Vol. 172, №. 4. P. 409-415. DOI:10.1093/rpd/ncv492.; Garzón W.J., Kramer R., Khoury H.J., et al. Estimation of organ doses to patients undergoing hepatic chemoembolization procedures // Journal of Radiological Protection. 2015. Vol. 35, №. 3. P. 629.; Hidajat N., Wust P., Felix R., Schröder R.J. Radiation exposure to patient and staff in hepatic chemoembolization: risk estimation of cancer and deterministic effects // Cardiovascular and interventional radiology. 2006. Vol. 29, №. 5. P. 791-796.; Tapiovaara M., Siiskonen T. PCXMC: A Monte Carlo program for calculating patient doses in medical x-ray examinations. 2nd Ed. STUK, Finalnd; 2008. 49 p.; International Commission on Radiological Protection 1990 Recommendations of the International Commission on Radiological Protection. ICRP Publication 60 Ann ICRP 1991; 21:1–201.; International Commission on Radiological Protection. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP Publication 103, Ann ICRP. 2007. Vol 37. P. 1–332.; Efstathopoulos E.P., Brountzos E.N., Alexopoulou E., et al. Patient radiation exposure measurements during interventional procedures: a prospective study // Health Physics. 2006. Vol. 91, №. 1. P. 36-40. DOI:10.1097/01.HP.0000198783.10855.51.; https://www.radhyg.ru/jour/article/view/803
-
3Academic Journal